Effect of long-acting somatostatin analog (somatulin) on renal hyperfiltration in patients with IDDM

Diabetes Care

Volumn 20, Issue 4, 1997, Pages 632-636

  Jacobs, Marloes L ^a   Derkx, Frans H M ^a   Stijnen, Theo ^b   Lamberts, Steven W J ^a   Weber, Rob F A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030898509     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.4.632     Document Type: Article

References (26)

1. Nathan DM: Long-term complications of diabetes mellitus. N Engl J Med 328:1676-1685, 1993
2. Selby JV, FitzSimmons SC, Newman JM, Katz PP, Sepe S, Showstack J: The natural history and epidemiology of diabetic nephropathy. JAMA 263:1954-1960, 1990
3. Mogensen CE: Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest 46:201-206, 1986
4. Azevedo MJ, Gross JL: Follow-up of glomerular hyperfiltration in normoalbuminuric type I (insulin-dependent) diabetic patients (Letter). Diabetologia 34:611, 1991
5. Rudberg S, Persson B, Dahlquist G: Increased glomerular filtration rate as a predictor of diabetic nephropathy: an 8-year prospective study. Kidney Int 41:822-828, 1992
6. Christiansen JS, Gammelgaard J, Frandsen M, Ørskov H, Parving H-H: Kidney function and size in type I (insulin-dependent) diabetic patients before and during growth hormone administration for 1 week. Diabetologia 22:333-337, 1982
7. Guler H-P, Eckardt K-U, Zapf J, Bauer C, Froesch ER: Insulin-like growth factor I increases glomerular nitration rate and renal plasma flow in man. Acta Endocrinol 121:101-106, 1989
8. Dullaart RPF, Meijer S, Marbach P, Sluiter WJ: Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients. Eur J Clin Invest 22:494-502, 1992
9. Christiansen JS: On the pathogenesis of the increased glomerular nitration rate in short-term insulin-dependent diabetes. Dan Med Bull 31:349-361, 1984
10. Blankestijn PJ, Derkx FHM, Birkenhäger JC, Lamberts SWJ, Mulder P, Verschoor L, Schalekamp MADH, Weber RFA: Glomerular hyperfiltration in insulin-dependent diabetes mellitus is correlated with enhanced growth hormone secretion. J Clin Endocrinol Metab 77:498-502, 1993
11. Jacobs ML, Nathoe HMW, Blankestijn PJ, Stijnen TH, Weber RFA: Growth hormone responses to growth hormone-releasing hormone and clonidine in patients with type I diabetes and in normal controls: effect of age, body mass index and sex. Clin Endocrinol 44:547-553, 1996
12. Plumb M, Nath K, Seaquist ER: Hypopituitarism stabilizes the renal and retinal complications of diabetes mellitus. Am J Nephrol 12:265-267, 1992
13. Serri O, Beauregard H, Brazeau P, Abribat T, Lambert J, Harris A, Vachon L: Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 265:888-892, 1991
14. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, Kuhn JM: Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 76:721-727, 1993
15. Zietse R, Blankestijn PJ, Pos B, Balk AHMM, Derkx FHM, Weimar W, Schalekamp MADH: Optimising glomerular filtration rate and effective renal plasma flow measurements using a simple pharmacokinetic model. Clin Nephrol 43:29-34, 1995
16. Daughaday WH, Mariz IK, Blethen SL: Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab 51:781-788, 1980
17. Vora J, Owens DR, Luzio S, Atiea J, Ryder R, Hayes TM: Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects. J Clin Endocrinol Metab 64:975-979, 1987
18. Møller J: Effects of growth hormone on human fluid homeostasis. In Growth Hormone in Adults. Juul A, Jørgensen JOL, Eds. Cambridge Univ. Press, New York, 1996, p. 220-233
19. Hirschberg R, Brunori G, Kopple JD, Guler H-P: Effects of insulin-like growth factor I on renal function in normal men. Kidney Int 43:387-397, 1993
20. Jaffa AA, LeRoith D, Roberts CT, Rust PF, Mayfield RK: Insulin-like growth factor I produces renal hyperfiltrarion by a kinin-mediated mechanism. Am J Physiol 266: F102-F107, 1994
21. Díez-Marqués ML, Garcia-Escribano C, Medina J, Boyano-Adanez MC, Arilla E, Torrecilla G, Rodríguez-Puyol D, Rodríguez-Puyol M: Effects of somatostatin on cultured human mesangial cells. Endocrinology 136:3444-3451, 1995
22. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM: Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinol 120:187-194, 1989
23. Cohen RM, Abplanalp WA: Resistance of growth hormone secretion to somatostatin in men with type I diabetes mellitus. Diabetes 40:1251-1258, 1991
24. Londong JE, Angerer M, Kutz K, Landgraf R, Londong V: Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 96:713-722, 1989
25. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ: Octreotide. N Engl J Med 334:246-254, 1996
26. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert J-P, Vague P: Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes Metab 18:438-444, 1992